How i treat the peripheral T-cell lymphomas

Alison J. Moskowitz, Matthew A. Lunning, Steven M. Horwitz

Research output: Contribution to journalArticlepeer-review

121 Scopus citations


The peripheral T-cell lymphomas (PTCLs) encompass a heterogeneous group of diseases that have generally been associated with poor prognosis. The most common PTCLs, peripheral T-cell lymphoma, not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALK-negative), despite their unique presentations and histologies, are currently treated similarly. Here we discuss our general approach to the treatment of the most common PTCLs. Based on the best data currently available, which include retrospective analyses and phase 2 prospective studies, ourapproach has involved cyclophosphamide, doxorubicin, vincristine, prednisone-based therapy followed by consolidation in first remission with autologous stemcell transplant. This treatment strategy likely improves the outcomefor patients compared with historical series; however,progressionfree survival rates remain disappointing, ranging from 40%to 50%. This is currently an exciting time in the treatment of PTCL due to the advent of recently approved drugs as well as new targeted agents currently under investigation. In addition, gene expression profiling is allowing for a better understanding of underlying disease biology, improved diagnostic accuracy, and prognostication in PTCL. As a result, over the next few years, we expect a significant shift in our management of these diseases with a move toward more individualized therapy leading to improved outcomes.

Original languageEnglish (US)
Pages (from-to)2636-2644
Number of pages9
Issue number17
StatePublished - Apr 24 2014

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'How i treat the peripheral T-cell lymphomas'. Together they form a unique fingerprint.

Cite this